EFFICACY OF NICOTINAMIDE MONONUCLEOTIDE SUPPLEMENTATION (NMN) IN BLOOD NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) FOR ANTI-AGING IN ADULTS: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/gyj2gr52Keywords:
Adults, anti-aging, nicotinamide adenine dinucleotide, nicotinamide mononucleotideAbstract
Aging is a risk factor for various chronic diseases such as diabetes, dyslipidemia, metabolic, neurological, and cardiovascular disease, and other age-related disorders. Nicotinamide mononucleotide (NMN) is one of the endogenous intermediate molecules in nicotinamide adenine dinucleotide (NAD+) biosynthesis, and its biological function is known to be related to an increase in NAD+ concentration. NAD+ levels decline and are critical for human health and longevity. The material and methods using a systematic review of RCT, with participants of healthy adults aged between 20-65 years old, agreed to take NMN supplementation compared to Placebo. The inclusion criteria are RCT studies regarding NMN administration with an outcome to prevent aging using primary objective measurement of blood nicotinamide adenine dinucleotide (NAD) concentration. Trial quality was assessed using the JBI checklist. We included six studies with an average duration of intervention between 10-12 weeks with a dosage of NMN 250-900mg/day. All six studies showed that NMN supplementation can significantly improve blood NAD concentration and cause only mild adverse effects during the trial. In conclusion, NMN supplementation has a significant clinical impact in preventing adult aging.
References
Song Q, Zhou X, Xu K, Liu S, Zhu X, Yang J. The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. Advances in Nutrition. Published online 2023. doi:10.1016/j.advnut.2023.08.008
United Nations. World Population Prospects 2022.; 2022.
Igarashi M, Yamauchi T. Insight into the Application of Nicotinamide Mononucleotide (NMN) to Age-Related Disorders. Vol 2.; 2023.
Nadeeshani H, Li J, Ying T, Zhang B, Lu J. Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns. J Adv Res. 2022;37:267-278. doi:10.1016/j.jare.2021.08.003
Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018;27(3):529-547. doi:10.1016/j.cmet.2018.02.011
Alegre GFS, Pastore GM. NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health. Curr Nutr Rep. Published online September 1, 2023. doi:10.1007/s13668-023-00475-y
Hong W, Mo F, Zhang Z, Huang M, Wei X. Nicotinamide Mononucleotide: A Promising Molecule for Therapy of Diverse Diseases by Targeting NAD+ Metabolism. Front Cell Dev Biol. 2020;8. doi:10.3389/fcell.2020.00246
Katayoshi T, Uehata S, Nakashima N, et al. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebocontrolled trial. Sci Rep. 2023;13(1). doi:10.1038/s41598-023-29787-3
Okabe K, Yaku K, Uchida Y, et al. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Front Nutr. 2022;9. doi:10.3389/fnut.2022.868640
Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science (1979). 2021;372:1224-1229. https://www.science.org
Igarashi M, Nakagawa-Nagahama Y, Miura M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. npj Aging. 2022;8(1). doi:10.1038/s41514-022-00084-z
Huang H. A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults. Frontiers in Aging. 2022;3. doi:10.3389/fragi.2022.851698
Yi L, Maier AB, Tao R, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023;45(1):29-43. doi:10.1007/s11357-022-00705-1
Pascual-Torner M, Carrero D, Perez-Silva JG, et al. Comparative genomics of mortal and immortal cnidarians unveils novel keys behind rejuvenation. Proc Natl Acad Sci U S A. 2022;119(36). doi:10.1073/pnas.2118763119
Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481(7381):287-294. doi:10.1038/nature10760
Freije JMP, López-Otín C. Reprogramming aging and progeria. Curr Opin Cell Biol. 2012;24(6):757-764. doi:10.1016/j.ceb.2012.08.009
Cantó C, Menzies KJ, Auwerx J. NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell Metab. 2015;22(1):31-53. doi:10.1016/j.cmet.2015.05.023
Ramanathan C, Lackie T, Williams DH, Simone PS, Zhang Y, Bloomer RJ. Oral Administration of Nicotinamide Mononucleotide Increases Nicotinamide Adenine Dinucleotide Level in an Animal Brain. Nutrients. 2022 Jan 12;14(2):300.
Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y, et al. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metab. 2016 Dec 13;24(6):795–806.
The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. Adv Nutr. 2023 Nov 1;14(6):1416–35.
Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns. Journal of Advanced Research. 2022 Mar 1;37:267–78.
Hong W, Mo F, Zhang Z, Huang M, Wei X. Nicotinamide Mononucleotide: A Promising Molecule for Therapy of Diverse Diseases by Targeting NAD+ Metabolism. Front Cell Dev Biol. 2020 Apr 28;8:246.
Kane AE, Sinclair DA. Sirtuins and NAD in the Development and Treatment of Metabolic and Cardiovascular Diseases. Circ Res. 2018 Sep 14;123(7):868–85.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
